November 18, 2026
Health news, explained with evidence
LIVE

Study of 750,000 Pregnancies Suggests Underlying Diabetes May Drive Preterm Risk in GLP-1 Users

🔬 Research 2 min read 👁 6

A large-scale study analyzing over 750,000 pregnancies found that GLP-1 receptor agonist medications were linked to preterm birth only when prescribed for diabetes, not for weight management.

Study of 750,000 Pregnancies Suggests Underlying Diabetes May Drive Preterm Risk in GLP-1 Users🔬Research

Photo: ScienceDaily Fitness

Key points

  • Analyzed over 750,000 pregnancies using nationwide Danish health registries.
  • Preterm birth risk associated with GLP-1 drugs appeared only in patients treated for diabetes.
  • No significant link to premature delivery was observed among women taking the medications for weight management.

A major investigation tracking more than 750,000 pregnancies has revealed that unintended exposure to popular weight loss and diabetes medications—such as Ozempic, Wegovy, and Saxenda—around the time of conception carries different risks depending on the underlying health condition for which it was prescribed. Researchers found that women who accidentally used these GLP-1 receptor agonists shortly before or during early pregnancy experienced a higher likelihood of premature delivery, but this association appeared exclusively in patients treated for existing diabetes.

Conversely, among women taking the identical medications strictly for weight management, the data showed no significant link to premature birth or other evaluated pregnancy complications. Led by a team at Copenhagen University Hospital Hvidovre in Denmark and published in Human Reproduction Open, the nationwide registry study evaluated deliveries between 2009 and 2023, identifying 529 pregnancies with potential early-period exposure. Investigators adjusted for numerous confounding factors, including maternal age, body mass index, smoking habits, and socioeconomic status.

Current clinical guidance generally advises discontinuing GLP-1 therapies roughly two months before attempting conception, primarily due to preliminary animal data. However, senior researcher Professor Henriette Svarre Nielsen noted that widespread global adoption makes inadvertent early-stage exposure increasingly common. First author Dr. Kathrine Hviid pointed out that these insights can better inform clinical counseling, suggesting that the underlying metabolic condition of diabetes, rather than the pharmaceutical agents themselves, may be the primary factor driving the elevated preterm delivery risk.

What to know: While the observational findings offer reassuring context for women who accidentally use GLP-1 drugs early in a pregnancy for weight control, current medical guidelines still advise stopping these treatments prior to planned pregnancies. Always consult a healthcare professional for personalized medical advice and guidance regarding medication management.

Source ScienceDaily Fitness — sciencedaily.com/releases/2026/11/261111005911.htm ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.